 |
|
Successful Treatment of Relapsed Acute Promyelocytic Leukemia in a Patient Receiving Continuous Ambulatory Peritoneal Dialysis With Oral Arsenic Trioxide
Arch Intern Med. 2005;165:1067-1068.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Serious medical comorbidities generally preclude curative therapies for patients with leukemia. Arsenic trioxide (As2O3), both intravenous and oral, is highly effective for acute promyelocytic leukemia (APL).1 As arsenic is eliminated mainly by renal excretion, uremic patients are considered unsuitable for arsenic trioxide therapy. To our knowledge, there are no data on arsenic clearance during dialysis. A patient with APL who was receiving continuous ambulatory peritoneal dialysis (CAPD) was successfully treated with oral arsenic trioxide. We took this unique opportunity to study arsenic clearance during CAPD.
Report of a Case
A 65-year-old woman with diabetes mellitus, ischemic heart disease, and chronic renal failure who was receiving CAPD had a relapse of APL 18 months after a first complete remission (CR) that had been induced with all trans-retinoic acid. She achieved a second CR (CR2) after 23 days of oral arsenic trioxide therapy (5 mg/d).2 There were no significant adverse effects (normal liver . . . [Full Text of this Article]
Comment
AUTHOR INFORMATION
Wing-Yan Au, MRCP;
Giselle T. Cheung, BSc;
Tommy W. Yuen, PhD;
Cyrus R. Kumana, MD;
Yok-Lam Kwong, MD
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells
Leung et al.
Blood 2007;109:740-746.
ABSTRACT
| FULL TEXT
Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety
Siu et al.
Blood 2006;108:103-106.
ABSTRACT
| FULL TEXT
Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Au et al.
Blood 2006;107:3012-3013.
FULL TEXT
|
